Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Bone Marrow Transplantation · 2025-02 · 60 (2) · 154-160
DOI: 10.1038/s41409-024-02447-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone Marrow Transplantation, online erschienen am 06.11.2024. Verfasst von Gege Gui und 22 weiteren Autor:innen. Beteiligte Einrichtung: Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Isocitrate Dehydrogenase, Mutation, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI), FNIH Biomarkers Consortium project MRD in AML.
Abstract (Originalsprache)
Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3 -ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoietic cell transplant (alloHCT) associates with increased relapse and death after transplant. The prognostic implications of persistence of other common AML-associated mutations, such as IDH1 , at this treatment landmark however remain incompletely defined. We performed testing for residual IDH1 variants ( IDH1 m) in pre-transplant CR1 blood of 148 adult patients undergoing alloHCT for IDH1 -mutated AML at a CIBMTR reporting site between 2013 and 2019. No statistically significant post-transplant differences were observed between those testing IDH1 m positive ( n = 53, 36%) and negative pre-transplant (overall survival (OS): p = 0.4; relapse: p = 0.5). For patients with IDH1 mutated AML co-mutated with NPM1 and/or FLT3 -ITD, only detection of persistent mutated NPM1 and/or FLT3 -ITD was associated with significantly higher rates of relapse ( p = 0.01). These data, from the largest study to date, do not support the detection of IDH1 mutation in CR1 blood prior to alloHCT as evidence of AML MRD for increased post-transplant relapse risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC, USA.
- Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
- Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
- Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN, USA.
- The Ohio State University College of Medicine, Columbus, OH, USA.
- University of Virginia, Charlottesville, VA, USA.
ORCID-Profile: Niveditha Ravindra, Zoë Wong, Jeffery J Auletta, Yi-Bin Chen, Steven M Devine, Antonio Martin Jimenez Jimenez, Marcos J G De Lima, Mark R Litzow, Partow Kebriaei, Stephen R Spellman, Laura W Dillon
Förderung
- NCI NIH HHS
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- FNIH Biomarkers Consortium project MRD in AML
Zitieren
APA
Gui, G., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y. B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., De Lima, M. J. G., Litzow, M. R., Kebriaei, P., Saber, W., Spellman, S. R., …, & Hourigan, C. S. (2025). Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplantation, 60(2), 154-160. https://doi.org/10.1038/s41409-024-02447-4
Vancouver
Gui G, Ravindra N, Hegde PS, Andrew G, Mukherjee D, Wong Z, et al. Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplantation. 2025;60(2):154-160. doi:10.1038/s41409-024-02447-4
BibTeX
@article{Gui2025,
author = {Gui, Gege and Ravindra, Niveditha and Hegde, Pranay S and Andrew, Georgia and Mukherjee, Devdeep and Wong, Zoë and Auletta, Jeffery J and El Chaer, Firas and Chen, Evan C and Chen, Yi-Bin and Corner, Adam and Devine, Steven M and Iyer, Sunil G and Jimenez Jimenez, Antonio Martin and De Lima, Marcos J G and Litzow, Mark R and Kebriaei, Partow and Saber, Wael and Spellman, Stephen R and Zeger, Scott L and Page, Kristin M and Dillon, Laura W and Hourigan, Christopher S},
title = {Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia},
journal = {Bone Marrow Transplantation},
year = {2025},
volume = {60},
number = {2},
pages = {154--160},
doi = {10.1038/s41409-024-02447-4}
}
EUVIMED